Novo Nordisk A/S experienced a significant surge in European trading following the announcement of positive early-stage trial results for its new obesity treatment, amycretin. The drug showed a remarkable 22% weight loss in patients over 36 weeks, boosting investor confidence and reversing negative sentiment. The once-weekly injection of amycretin outperformed a placebo, which resulted in a 2% weight gain in the same timeframe.
Martin Lange, Novo’s executive vice president for Development, expressed optimism about the trial results, highlighting the potential of amycretin as a novel treatment for obesity. The company’s shares saw a substantial increase of up to 14% in Copenhagen, marking the largest intra-day gain since August 8, 2023. Despite a recent decline in stock value, Novo’s super bull, Goldman’s James Quigley, remains bullish on the company, maintaining a “Buy” rating with a 875 Danish krone price target over the next 12 months.
Quigley emphasized the promising results of amycretin and its competitive edge in the obesity treatment market. He believes that further weight loss potential can be demonstrated over a longer period, potentially exceeding the initial 22% weight loss. The positive outlook on Novo’s future is a welcome change after the disappointment surrounding the company’s previous weight loss drug, CagriSema.
Barclays analyst Emily Field echoed Quigley’s sentiments, stating that Novo’s latest trial results have shifted the negative sentiment surrounding the company. The data indicates that amycretin could be a game-changer in the weight loss drug market, combining two effective mechanisms in a single molecule. This development comes at a crucial time as the industry navigates through changing dynamics, including the potential impact of new regulatory changes.
Overall, Novo Nordisk’s innovative approach to obesity treatment with amycretin has the potential to reinvigorate investor interest and position the company as a key player in the pharmaceutical market. As the company continues to advance its research and development efforts, the future looks promising for Novo and its groundbreaking obesity treatment.